Department of Kidney, Shandong Provincial Hospital, Shandong University, Jinan, China.
Nephrology (Carlton). 2010 Feb;15(1):27-32. doi: 10.1111/j.1440-1797.2009.01162.x.
Long-term peritoneal dialysis (PD) may lead to peritoneal fibrosis and ultrafiltration failure. It had been demonstrated that the renin-angiotensin system (RAS) plays a key role in the regulation of peritoneal function in rats on PD. We investigated the effects of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) on long-term PD patients.
We analyzed data from 66 patients treated with PD therapy at our centre for at least 12 months retrospectively, during which time at least two peritoneal equilibration tests (PET) were performed. Thirty-eight patients were treated with ACE/angiotensin II (AII) inhibitors (ACE/ARB group); the other 28 received none of the above drugs during the entire follow up (control group). The expression of fibronectin, transforming growth factor-beta1 (TGF-beta1), Aquaporin1 (AQP1) and vascular endothelial growth factor (VEGF) in the overnight effluent were examined by enzyme-linked immunosorbent assay.
The demographic data of the two groups showed no difference during the study. No difference between the groups was found with respect to residual renal function (RRF) at the start for both groups by the end of follow up, decreased in the vast majority of patients from both groups (P = 0.014). After 12 months, a significant difference in ultrafiltration was found between the two groups: in the control group it had decreased, while it had not changed in the ACE/ARB group (P < 0.05). In comparison with the baseline level, expression of fibronectin, TGF-beta1 and VEGF in dialysate effluent were significantly increased except for AQP1 in the control group (P < 0.05), but not in the ACE/ARB group (P > 0.05).
The findings suggest that ACE/AII inhibitors appeared to have a slower rate of decline in ultrafiltration and RRF, effectively protect against peritoneal fibrosis in long-term peritoneal dialysis. Long-term follow up seems to be required to draw more conclusions.
长期腹膜透析(PD)可导致腹膜纤维化和超滤衰竭。已经证明,肾素-血管紧张素系统(RAS)在 PD 大鼠的腹膜功能调节中起着关键作用。我们研究了血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体阻滞剂(ARB)对长期 PD 患者的影响。
我们回顾性分析了在我们中心接受 PD 治疗至少 12 个月的 66 例患者的数据,在此期间至少进行了两次腹膜平衡试验(PET)。38 例患者接受 ACE/血管紧张素 II(AII)抑制剂治疗(ACE/ARB 组);其余 28 例患者在整个随访期间未使用上述任何药物(对照组)。通过酶联免疫吸附试验检测 overnight effluent 中纤维连接蛋白、转化生长因子-β1(TGF-β1)、水通道蛋白 1(AQP1)和血管内皮生长因子(VEGF)的表达。
两组患者的人口统计学数据在研究过程中无差异。两组患者的残余肾功能(RRF)在研究开始时无差异,但在随访结束时均有下降,且绝大多数患者的 RRF 均下降(P = 0.014)。12 个月后,两组间超滤量存在显著差异:对照组超滤量减少,而 ACE/ARB 组超滤量无变化(P < 0.05)。与基线水平相比,对照组透析液 effluent 中纤维连接蛋白、TGF-β1 和 VEGF 的表达明显增加,而 AQP1 除外(P < 0.05),但 ACE/ARB 组无变化(P > 0.05)。
研究结果表明,ACE/AII 抑制剂似乎能更缓慢地降低超滤量和 RRF,有效防止长期腹膜透析中的腹膜纤维化。需要进行长期随访以得出更多结论。